CpG island methylation of DNA damage response genes in advanced ovarian cancer

We have determined the methylation frequencies of 24 CpG islands of genes associated with DNA damage responses or with ovarian cancer in 106 stage III/IV epithelial ovarian tumors. We have analyzed this data for whether there is evidence of a CpG island methylator phenotype or associations of CpG is...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2005-10, Vol.65 (19), p.8961-8967
Main Authors: TEODORIDIS, Jens M, HALL, Jacqueline, BROWN, Robert, MARSH, Sharon, KANNALL, Hilary D, SMYTH, Catriona, CURTO, Jorge, SIDDIQUI, Nadeem, GABRA, Hani, MCLEOD, Howard L, STRATHDEE, Gordon
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
CpG Islands
DNA (Cytosine-5-)-Methyltransferases - genetics
DNA Damage - genetics
DNA Methylation
DNA Methyltransferase 3B
Female
Female genital diseases
Genotype
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
Neoplasm Staging
Ovarian Neoplasms - enzymology
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Polymorphism, Genetic
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have determined the methylation frequencies of 24 CpG islands of genes associated with DNA damage responses or with ovarian cancer in 106 stage III/IV epithelial ovarian tumors. We have analyzed this data for whether there is evidence of a CpG island methylator phenotype or associations of CpG island methylation with response to chemotherapy in advanced ovarian cancer. Frequent methylation was observed for OPCML, DCR1, RASSF1A, HIC1, BRCA1, and MINT25 (33.3%, 30.7%, 26.4%, 17.3%, 12.3%, and 12.0%, respectively), whereas no methylation was observed for APAF-1, DAPK, FANCF, FAS, P14, P21, P73, SOCS-3, and SURVIVIN. The remaining genes showed only a low frequency of methylation,
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-05-1187